Please assess the completion status of the following clinical trial:

Trial Title: Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with multiple sclerosis for at least 6 months~* Neurogenic detrusor overactivity without DSD~* Symptoms of OAB~* Patients capable of completing the bladder diary~* Patients capable of independent toileting~* Patients able to swallow the study medication in accordance to the protocol~* Body Mass Index \>/= 18,8 kg/qm and \</= 35,0 kg/qm~* documented, dated, written informed consent~Exclusion Criteria:~* Treatment with drugs known to affect mainly the urinary function 14 days prior to starting completion of the baseline diary for Visit 2~* Participation in a bladder-training program~* Low compliance bladder (Compliance \<20 mL/cm H2O)~* DSD, Detrusor hyporeflexia / areflexia and bradykinesia / tremor of the external urethral sphincter~* Indwelling catheter or intermittent self-catheterization~* Patience with post-void residual (PVR) urinary volume \> 200 mL at baseline~* Urinary retention or clinically significant bladder outlet obstruction as detected by the investigator~* Clinically predominant and bothersome stress urinary incontinence~* Neurological diseases other than multiple sclerosis affecting urinary bladder function~* Any urogenital surgery within 12 month prior to Visit 1~* 17 Additional Exclusion Criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).